Insulin-Like Somatomedin Peptide I (IGF-I), also known as Somatomedin C, is a hormone that plays a crucial role in growth and development, as well as various metabolic processes in the human body. IGF-I belongs to the insulin-like growth factor family, which also includes IGF-II. It is primarily produced in the liver under the stimulation of growth hormone (GH) secreted by the pituitary gland.
IGF-I exhibits structural similarities to insulin, hence its name. However, its functions are distinct from those of insulin. IGF-I acts as a mediator of the effects of GH and is involved in cell growth, proliferation, and differentiation. It exerts its biological actions by binding to its receptor, the IGF-I receptor, which is present in various tissues throughout the body.
IGF-I not only promotes tissue growth during childhood and adolescence but also facilitates tissue repair and regeneration in adults. It stimulates protein synthesis, resulting in increased muscle mass and strength. Additionally, IGF-I aids in the regulation of glucose metabolism and lipid metabolism, playing a role in the maintenance of blood sugar levels and body weight.
An imbalance in IGF-I levels can have significant implications for human health. Deficiencies in IGF-I can lead to growth disorders, such as short stature or delayed growth. Conversely, excessive production of IGF-I has been associated with certain types of cancer and may contribute to tumor growth and progression.
In summary, Insulin-Like Somatomedin Peptide I (IGF-I) is a hormone that regulates growth, cellular processes, and metabolic functions in the human body. It is produced in the liver under the influence of growth hormone and binds to the IGF-I receptor to exert its effects.
